By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Coming Soon
The ability of a 3D printed capsule co-formulated with the permeation enhancer sodium caprate to transport the synthetic octapeptide octreotide in beagle dogs was assessed.
The capsule is made to break free from the physiological pressures in the antropyloric area. Traditional enteric coated hard gelatin capsules and enteric coated tablets were contrasted with the pressure sensitive capsules.
Using a bottom-up assembly method, 3D biological structures are created by depositing biomaterials or biomaterials combined with cells in predefined patterns layer by layer.
Replicating the structure, makeup, and complexity of human tissues is now possible thanks to technology, which could ultimately result in the development of whole organ engineering for medical applications.
The Global 3D bioprinted capsules market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
The multinational pharmaceutical giant Merck has made plans to collaborate with AMCM, an EOS Group company that creates specialised additive manufacturing equipment.
The two businesses will collaborate on designing and manufacturing 3D printed tablets, initially for use in clinical trials and subsequently for mass production.
“Our relationship with AMCM / EOS has the potential to change the way tablets are made,” said Merck’s Chief Strategy Officer. The sector will undergo a significant shift toward digitization.
The purpose of powder bed fusion, in which powder is melted and fused together layer by layer by a laser, is to create pharmaceuticals. AM is anticipated to speed up and reduce the cost of tablet manufacturing by enabling the avoidance of reformulations during pharmaceutical development and commercial production. Additionally, 3D printing offers the flexibility to adjust to patient needs.
